Pull to refresh
Logo
What Changed
Following Why Sign Up
Massachusetts hospitals sue Eli Lilly over 340B patient data demands

Massachusetts hospitals sue Eli Lilly over 340B patient data demands

Rule Changes Boston, MA local

Five hospitals say Lilly withheld drug discounts to force disclosure of protected claims data.

Today: Five Massachusetts hospitals sue Eli Lilly

Overview

Updated 58 minutes ago

Five Massachusetts hospitals sued Eli Lilly in federal court in Boston, saying the drugmaker cut off discounted drug prices to force them to hand over patient claims data. The hospitals include Massachusetts General, Brigham and Women's, Salem, and two UMass Memorial facilities.

Under the 340B program, drugmakers must discount outpatient drugs for hospitals serving low-income patients. Lilly says it needs the data to catch double-dipping; the hospitals call the requirement illegal and say it threatens patient privacy and community programs.

Why it matters

The case tests whether drugmakers can attach data demands to 340B discounts, with tens of millions in hospital savings at stake.

Last Monday's email for Boston, MA

Sent Nov 2. It carried:

Get next Monday's: one short email a week. Free. Unsubscribe in one click.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

5
Massachusetts hospitals suing Lilly
Mass General, Brigham and Women's, Salem, UMass Memorial Medical Center, and UMass Memorial Health — Harrington.
$20M
Annual 340B savings at stake for UMass Memorial
Hospitals say they are paying higher drug costs themselves while refusing Lilly's data terms.
$100
Liability cap in Lilly's data platform terms
Hospitals cite the cap as evidence that the platform terms are one-sided.
Jan 2026
Lilly policy announced
Lilly began requiring claims data through a third-party platform to receive 340B discounts.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

DG
Dr. Patrick Gordan
Associate Chief Medical Officer, Salem Hospital
Spokesperson for plaintiff hospitals
DD
Dr. Eric Dickson
President and CEO, UMass Memorial Health
Leader of plaintiff health system
 Catherine Hanaway
Catherine Hanaway
Missouri Attorney General
Issued cease-and-desist letter to Eli Lilly

Organizations Involved

Eli Lilly and Company
Eli Lilly and Company
Pharmaceutical company
Defendant

Indianapolis-based drugmaker with a $700 million research center in Boston.
Mass General Brigham
Mass General Brigham
Nonprofit health system
Plaintiff

Integrated academic health system that includes Massachusetts General Hospital and Brigham and Women's Hospital.
MH
UMass Memorial Health
Nonprofit health system
Plaintiff

Health system that includes UMass Memorial Medical Center and UMass Memorial Health — Harrington.
Missouri Attorney General’s Office
Missouri Attorney General’s Office
State law enforcement agency
Issued cease-and-desist letter to Lilly

Missouri state agency that enforces consumer protection law.

Timeline

January 2026 November 2026

5 events Latest: Today
Tap a bar to jump to that date

  1. Five Massachusetts hospitals sue Eli Lilly

    Today Legal

    The hospitals allege corporate extortion and ask a federal court to restore 340B discounts and block the data requirement.

  2. Missouri AG sends cease-and-desist to Lilly

    Legal

    Catherine Hanaway says the data policy violates state consumer protection law and threatens legal action.

  3. Lilly cuts off University of Missouri Health Care discounts

    Legal

    Missouri's attorney general later cites the cutoff in a cease-and-desist letter to Lilly.

  4. Lilly begins enforcing data requirement

    Policy

    The policy takes effect for a subset of hospitals, covering in-house and contract pharmacy dispenses.

  5. Lilly announces 340B claims-data policy

    Policy

    Lilly says hospitals must submit claims data through a third-party platform to receive 340B discounts.

Scenarios

1

Court blocks Lilly's data requirement while lawsuit proceeds

Possible Resolves by Q1 2027

Discussed by: Hospital plaintiffs' complaint

The hospitals ask the court to stop Lilly from withholding 340B discounts during the case. A preliminary injunction would restore discounts while the privacy and contract claims are litigated.

2

Lilly settles and revises data platform terms

Possible Resolves by Q2 2027

Discussed by: Court filings and prior 340B litigation

A settlement could change the platform's data-use and liability terms, restoring discounts without a final ruling. The hospitals have said they support audits and oversight, leaving room for a privacy compromise.

3

Court upholds Lilly's policy, hospitals must comply or lose discounts

Unlikely Resolves by End of 2027

Discussed by: Lilly's public statements

Lilly argues the data is already routinely shared with insurers and is needed to prevent double discounts. A final ruling for Lilly would let it condition 340B discounts on claims-data submission.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

1992

340B Drug Pricing Program created (1992)

Congress required drugmakers to discount outpatient drugs for certain hospitals and clinics that serve low-income patients. The program became a major source of savings for community health programs.

Then

Hospitals used the discounts to fund care for uninsured and underinsured patients.

Now

Disputes later focused on which entities qualify and what conditions drugmakers can impose.

Why this matters now

The current lawsuit is about whether a drugmaker can add a data requirement to the discounts the program guarantees.

2020s

Contract pharmacy restrictions (2020s)

Drugmakers began limiting 340B discounts when drugs were dispensed through contract pharmacies, and hospitals and states pushed back. Some states passed laws barring the restrictions, prompting litigation.

Then

Courts split on whether the restrictions were allowed.

Now

The fight established that conditions on 340B discounts are legally contested.

Why this matters now

Lilly's data demand is another condition on 340B discounts, and hospitals say if allowed it will spread to other drugmakers.

Sources

(3)
Boston.com Mass General Brigham Fierce Healthcare